Trial · NCT06653686
Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory Gout
NCT06653686, Not applicable, Not yet recruiting, The First Hospital of Jilin University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory Gout. Trials, record NCT06653686. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06653686
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory Gout
- NCT number
- NCT06653686
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 128 participants, estimated
- Lead sponsor
- The First Hospital of Jilin University
- Conditions
- Refractory Gout
- Interventions
- Hyperthermia combined with oral febuxostat., Febuxostat
- First posted
- 2024-10-22
- Last updated
- 2024-10-22
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The number of gout flares during the treatment period | From enrollment to the end of treatment at 20 weeks | |
| Secondary | The proportion of patients experiencing ≥1 or ≥2 gout flares during the treatment period | From enrollment to the end of treatment at 20 weeks | |
| Secondary | The time to the first gout flare during the treatment period | From enrollment to the end of treatment at 20 weeks | |
| Secondary | Changes in serum uric acid levels by the end of the treatment period | From enrollment to the end of treatment at 20 weeks | Serum uric acid levels will be measured using Uricase-UV method. The change in uric acid levels from baseline to the end of the treatment period will be analyzed. |
| Secondary | Proportion of patients achieving target uric acid levels by the end of the treatment period | From enrollment to the end of treatment at 20 weeks | The proportion of patients achieving a target serum uric acid level of \< 360μmol/L will be calculated at the end of the treatment period, using Uricase-UV method to assess uric acid levels. |
| Secondary | Percentage reduction in febuxostat dosage by the end of the treatment period | From enrollment to the end of treatment at 20 weeks | Percentage reduction in febuxostat dosage by the end of the treatment period, investigating changes in febuxostat dosage in the trial and control groups during the study. |
| Secondary | Changes in the volume of monosodium urate (MSU) in target joints by the end of the treatment period | From enrollment to the end of treatment at 20 weeks | |
| Secondary | Changes in C-reactive protein (CRP) levels by the end of the treatment period | From enrollment to the end of treatment at 20 weeks | CRP will be measured using the immunoturbidimetric method, and changes from baseline to the end of the treatment period will be evaluated. |
| Secondary | Changes in erythrocyte sedimentation rate (ESR) by the end of the treatment period | From enrollment to the end of treatment at 20 weeks | ESR will be measured using an instrument-based method, and changes from baseline to the end of the treatment period will be assessed. |
| Secondary | Changes in TH1/TH2-related cytokines by the end of the treatment period | From enrollment to the end of treatment at 20 weeks | These cytokines will be measured using flow cytometry, and changes from baseline to the end of the treatment period will be evaluated. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06653686
GET https://conductscience.org/api/trials/v1/NCT06653686/registered